According to the latest report by Renub Research, titled "Diabetes Drug Market Global & Forecast By Disease, Oral Therapy, Injection, Insulin, Regions, Company" Diabetes drugs are used to treat pre-diabetes and diabetes mellitus type 2 by controlling the blood glucose level of the body. There are different classes of medicine for the treatment of this diabetes, which are given to patients through oral, intravenous, and subcutaneous routes. According to Renub Research analysis, Global Diabetes Drug Market is forecasted to be US$ 78.10 Billion by 2026. This growth is due to the rising number of diabetes patients worldwide, increasing per capita income. Another reason is with the use of machines; people are following a sedentary lifestyle, which leads to obesity, a decline of physical activity, and consumption of unhealthy meals. Besides, growth in the ageing population is also one of the other reason.
COVID-19 impact on Diabetes Drug Market
Most of the countries are affected by COVID-19 pandemic, the healthcare system and economic activities are disturbed by lockdown imposed by governments. Currently, treatment of COVID-19 is the priority of healthcare department, and hospitals have stopped treatment of other diseases as beds are reserved for COVID-19 patients. Diabetes patients have to depend on medicines prescribed by doctors, and governments are investing heavily in their healthcare systems. This will also help in research and development of diabetes drugs which is propelled by massive investment in the pharma industry.
Market Summary:
By Disease: This research report has covered the market of Type 1, Type 2 diabetes, according to Renub Research analysis.
Oral Therapy: The market for following Oral Therapies is covered in this report, such as Biguanide, SGLT-2, Alpha Glucosidase Inhibitor, (DPP) IV Inhibitor, and Others Oral Drug.
By Injection: This report gives the market for following injection Glucagon-like peptide (GLP) 1 agonist, Amylin receptor against
By Insulin: The market for following insulin types are covered in the research report: Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin, and Other Insulin.
By Regions: The following regions are covered in the research report Japan, India, United States, 5European Union, Canada, China, and Brazil.
By Company: Overview, R&D Pipeline and Sales Analysis of Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson are given in the research report.
About Company:
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Life Sciences, Information Technology, Telecom, Financial Services (Banking, Insurance), Energy, Retail, Manufacturing, Automotive, and Social sector. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Contact Us:
Renub Research
Phone No: +1 678-302-0700 (USA) | +91-120-421-9822 (IND)
Email: info@renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research